86 related articles for article (PubMed ID: 25231113)
21. Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.
Zaitseva L; Murray MY; Shafat MS; Lawes MJ; MacEwan DJ; Bowles KM; Rushworth SA
Oncotarget; 2014 Oct; 5(20):9930-8. PubMed ID: 25294819
[TBL] [Abstract][Full Text] [Related]
22. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma.
Marinaccio C; Ingravallo G; Gaudio F; Perrone T; Nico B; Maoirano E; Specchia G; Ribatti D
Leuk Res; 2014 Nov; 38(11):1374-7. PubMed ID: 25293515
[TBL] [Abstract][Full Text] [Related]
23. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
[TBL] [Abstract][Full Text] [Related]
24. A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.
Mian M; Marcheselli L; Rossi A; Visco C; Chiappella A; Volpetti S; Zaja F; Mondello P; Fiegl M; Billio A; Federico M; Luminari S; Rambaldi A; Cortelazzo S
Ann Oncol; 2014 Dec; 25(12):2398-2404. PubMed ID: 25274614
[TBL] [Abstract][Full Text] [Related]
25. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
[TBL] [Abstract][Full Text] [Related]
26. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.
Schatz JH; Horwitz SM; Teruya-Feldstein J; Lunning MA; Viale A; Huberman K; Socci ND; Lailler N; Heguy A; Dolgalev I; Migliacci JC; Pirun M; Palomba ML; Weinstock DM; Wendel HG
Leukemia; 2015 Jan; 29(1):237-41. PubMed ID: 25257991
[No Abstract] [Full Text] [Related]
27. High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.
Laursen MB; Reinholdt L; Schönherz AA; Due H; Jespersen DS; Grubach L; Ettrup MS; Røge R; Falgreen S; Sørensen S; Bødker JS; Schmitz A; Johnsen HE; Bøgsted M; Dybkær K
Oncotarget; 2019 Jan; 10(7):717-731. PubMed ID: 30774774
[TBL] [Abstract][Full Text] [Related]
28. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
29. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
[TBL] [Abstract][Full Text] [Related]
30. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Reddy A; Zhang J; Davis NS; Moffitt AB; Love CL; Waldrop A; Leppa S; Pasanen A; Meriranta L; Karjalainen-Lindsberg ML; Nørgaard P; Pedersen M; Gang AO; Høgdall E; Heavican TB; Lone W; Iqbal J; Qin Q; Li G; Kim SY; Healy J; Richards KL; Fedoriw Y; Bernal-Mizrachi L; Koff JL; Staton AD; Flowers CR; Paltiel O; Goldschmidt N; Calaminici M; Clear A; Gribben J; Nguyen E; Czader MB; Ondrejka SL; Collie A; Hsi ED; Tse E; Au-Yeung RKH; Kwong YL; Srivastava G; Choi WWL; Evens AM; Pilichowska M; Sengar M; Reddy N; Li S; Chadburn A; Gordon LI; Jaffe ES; Levy S; Rempel R; Tzeng T; Happ LE; Dave T; Rajagopalan D; Datta J; Dunson DB; Dave SS
Cell; 2017 Oct; 171(2):481-494.e15. PubMed ID: 28985567
[TBL] [Abstract][Full Text] [Related]
31. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526
[TBL] [Abstract][Full Text] [Related]
32. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Crump M; Neelapu SS; Farooq U; Van Den Neste E; Kuruvilla J; Westin J; Link BK; Hay A; Cerhan JR; Zhu L; Boussetta S; Feng L; Maurer MJ; Navale L; Wiezorek J; Go WY; Gisselbrecht C
Blood; 2017 Oct; 130(16):1800-1808. PubMed ID: 28774879
[TBL] [Abstract][Full Text] [Related]
33. CXCR4-targeted theranostics in oncology.
Buck AK; Serfling SE; Lindner T; Hänscheid H; Schirbel A; Hahner S; Fassnacht M; Einsele H; Werner RA
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4133-4144. PubMed ID: 35674738
[TBL] [Abstract][Full Text] [Related]
34. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
35. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
[TBL] [Abstract][Full Text] [Related]
36. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
Uhl B; Prochazka KT; Pansy K; Wenzl K; Strobl J; Baumgartner C; Szmyra MM; Waha JE; Wolf A; Tomazic PV; Steinbauer E; Steinwender M; Friedl S; Weniger M; Küppers R; Pichler M; Greinix HT; Stary G; Ramsay AG; Apollonio B; Feichtinger J; Beham-Schmid C; Neumeister P; Deutsch AJ
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887224
[TBL] [Abstract][Full Text] [Related]
37. Formation of Lymphoma Hybrid Spheroids and Drug Testing in Real Time with the Use of Fluorescence Optical Tweezers.
Duś-Szachniewicz K; Gdesz-Birula K; Nowosielska E; Ziółkowski P; Drobczyński S
Cells; 2022 Jul; 11(13):. PubMed ID: 35805197
[TBL] [Abstract][Full Text] [Related]
38. Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
[TBL] [Abstract][Full Text] [Related]
39. Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.
Kwon D; Takata K; Zhang Z; Chong L; Fraser B; Zeisler J; Miyata-Takata T; Merkens H; Rousseau J; Aoki T; Kuo HT; Tan R; Zhang C; Lau J; Villa D; Uribe CF; Lin KS; Steidl C; Benard F
Clin Cancer Res; 2022 Apr; 28(8):1628-1639. PubMed ID: 35078860
[TBL] [Abstract][Full Text] [Related]
40. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4.
Serna N; Carratalá JV; Conchillo-Solé O; Martínez-Torró C; Unzueta U; Mangues R; Ferrer-Miralles N; Daura X; Vázquez E; Villaverde A
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
